Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: BL-M07D1
Drug: PD-1 monoclonal antibody
Drug: Capecitabine

First Posted Date: 2024-05-21

Last Posted Date: 2024-07-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT06423885

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Neoplasms

Interventions: Radiation: Short-course radiotherapy
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Calcium Formate
Radiation: Long-course chemoradiation
Drug: Fluorouracil
Drug: Capecitabine

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Pei-Rong Ding

Target Recruit Count: 66

Registration Number: NCT06417476

Locations: 🇨🇳
651 Dongfeng Road East, Guangzhou, Guangdong, China

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Phase 3

Recruiting

Conditions: Triple-Negative Breast Cancer

Interventions: Biological: Pembrolizumab
Biological: sac-TMT
Drug: Capecitabine

First Posted Date: 2024-05-01

Last Posted Date: 2024-12-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1530

Registration Number: NCT06393374

Locations: 🇺🇸
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0041), Tulsa, Oklahoma, United States
🇦🇹
Klinikum Wels-Grieskirchen GmbH ( Site 1205), Wels, Oberosterreich, Austria
🇫🇷
Centre Antoine-Lacassagne ( Site 1308), Nice, Alpes-Maritimes, France

and more 115 locations

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Phase 2

Not yet recruiting

Conditions: RECTAL NEOPLASMS
Rectal Cancer

Interventions: Radiation: Radiotherapy
Drug: Tislelizumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2024-04-30

Last Posted Date: 2024-04-30

Lead Sponsor: Fudan University

Target Recruit Count: 46

Registration Number: NCT06390982

Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer

Phase 4

Not yet recruiting

Conditions: Pancreatic Cancer Non-resectable

Interventions: Drug: Huaier Granule
Drug: Capecitabine

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Health Science Center of Xi'an Jiaotong University

Target Recruit Count: 488

Registration Number: NCT06387368

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3

Recruiting

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: BL-B01D1
Drug: Eribulin
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Capecitabine

First Posted Date: 2024-04-24

Last Posted Date: 2024-07-05

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 436

Registration Number: NCT06382142

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Phase 1

Not yet recruiting

Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Interventions: Drug: Zumsemetinib
Drug: Capecitabine
Drug: Zoledronic acid
Drug: Denosumab

First Posted Date: 2024-04-18

Last Posted Date: 2024-11-19

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 152

Registration Number: NCT06374459

Locations: 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States